SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name: Ivermectin / Pyrantel Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture: Veterinary product

1.3 Details of the supplier of the safety data sheet
Company: MSD
Kilsheean
Clonmel Tipperary, IE

Telephone: 353-51-601000

E-mail address of person responsible for the SDS: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Short-term (acute) aquatic hazard, Category 1
Long-term (chronic) aquatic hazard, Category 1

H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms:

Signal word: Warning

Hazard statements: H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements: Prevention:
P273 Avoid release to the environment.
Response:
P391 Collect spillage.
Additional Labelling
The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.6 %

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Concentration (% w/w)</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)</td>
<td>22204-24-6 244-837-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&gt;= 1 - &lt; 10</td>
<td></td>
</tr>
<tr>
<td>Ivermectin</td>
<td>70288-86-7 274-536-0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Tox. 2; H300 Acute Tox. 3; H311 STOT SE 1; H370 STOT RE 1; H372 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000</td>
</tr>
</tbody>
</table>

>= 0.0025 - < 0.025
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.17  Revision Date: 27.08.2021  SDS Number: 52862-00020  Date of last issue: 09.04.2021
Date of first issue: 02.02.2015

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: No special precautions are necessary for first aid responders.

If inhaled: If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact: Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a
5.3 Advice for firefighters

Special protective equipment for firefighters: Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions: Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.
SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-</td>
<td>22204-24-6</td>
<td>TWA</td>
<td>250 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
</tbody>
</table>
## Ivermectin / Pyrantel Formulation

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>168 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>50 mg/m³</td>
</tr>
<tr>
<td>D-Glucono-1,5-lactone</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>59 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>11.9 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>14.6 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>5.9 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>5.9 mg/kg bw/day</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>443.28 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>443.28 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

### Further information:
- **Wipe limit**: 0.5 mg/100 cm²

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

- **Propylene glycol**
  - OELV - 8 hrs (TWA) (particles)
    - Value: 10 mg/m³
    - Category: Long-term local effects
  - OELV - 8 hrs (TWA) (total (vapour and particles))
    - Value: 150 ppm
    - Category: IE OEL
  - Derived No Effect Level (DNEL):
    - Value: 168 mg/m³
    - Category: Long-term systemic effects

- **Ivermectin**
  - TWA
    - Value: 0.05 mg/m³ (OEB 3)
    - Category: Internal

- **D-Glucono-1,5-lactone**
  - Derived No Effect Level (DNEL):
    - Value: 59 mg/m³
    - Category: Long-term systemic effects
Ivermectin / Pyrantel Formulation

### Effects

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Ingestion</th>
<th>Acute systemic effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propylene glycol</td>
<td>Fresh water</td>
<td>260 mg/l</td>
</tr>
<tr>
<td></td>
<td>Freshwater - intermittent</td>
<td>183 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>26 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>20000 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>572 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>57.2 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>50 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>D-Glucono-1,5-lactone</td>
<td>Fresh water</td>
<td>0.1 mg/l</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>Fresh water</td>
<td>0.01 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Intermittent use/release</td>
<td>1 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>6.498 mg/l</td>
</tr>
<tr>
<td></td>
<td>Fresh water sediment</td>
<td>0.36 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Marine sediment</td>
<td>0.36 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>0.014 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

### 8.2 Exposure controls

**Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

**Personal protective equipment**

**Eye protection**

Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Hand protection**

**Material**

Chemical-resistant gloves

**Remarks**

Consider double gloving.

**Skin and body protection**

Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>powder</td>
</tr>
<tr>
<td>Colour</td>
<td>brown</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>4 - 6 (20 °C) (as aqueous solution)</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td>Water solubility</td>
</tr>
<tr>
<td></td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Vapour pressure</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
Ivermectin / Pyrantel Formulation

Relative density: No data available
Density: No data available
Relative vapour density: Not applicable
Particle characteristics:
Particle size: No data available

9.2 Other information
Explosives: Not explosive
Oxidizing properties: The substance or mixture is not classified as oxidizing.
Evaporation rate: Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid
Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials
Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version: 2.17  Revision Date: 27.08.2021  SDS Number: 52862-00020  Date of last issue: 09.04.2021
Date of first issue: 02.02.2015

Components:

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity:
- LD50 (Rat): > 24,000 mg/kg
- LD50 (Mouse): > 24,000 mg/kg
- LD50 (Dog): 2,000 mg/kg

Ivermectin:

Acute oral toxicity:
- LD50 (Rat): 50 mg/kg
- LD50 (Mouse): 25 mg/kg
- LD50 (Monkey): > 24 mg/kg

Target Organs: Central nervous system
Symptoms: Vomiting, Dilatation of the pupil
Remarks: No mortality observed at this dose.

Acute inhalation toxicity:
- LC50 (Rat): 5.11 mg/l
  Exposure time: 1 h
  Test atmosphere: dust/mist

Acute dermal toxicity:
- LD50 (Rabbit): 406 mg/kg
- LD50 (Rat): > 660 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Ivermectin:

Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Ivermectin:

Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.
Respiratory sensitisation
Not classified based on available information.

**Components:**

**Ivermectin:**

<table>
<thead>
<tr>
<th>Exposure routes</th>
<th>Dermal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Species</td>
<td>Humans</td>
</tr>
<tr>
<td>Result</td>
<td>Does not cause skin sensitisation.</td>
</tr>
</tbody>
</table>

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

4,4’-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

**Ivermectin:**

Genotoxicity in vitro:
- Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative

  - Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
    - Test system: human diploid fibroblasts
    - Result: negative

  - Test Type: Mouse Lymphoma
    - Result: negative

**Carcinogenicity**
Not classified based on available information.

**Components:**

**Ivermectin:**

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>NOAEL</td>
<td>1.5 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Mouse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Route</td>
<td>Oral</td>
</tr>
<tr>
<td>NOAEL</td>
<td>2.0 mg/kg body weight</td>
</tr>
<tr>
<td>Result</td>
<td>negative</td>
</tr>
<tr>
<td>Remarks</td>
<td>Based on data from similar materials</td>
</tr>
</tbody>
</table>

**Reproductive toxicity**
Not classified based on available information.
Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal development:
- Test Type: Embryo-foetal development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: NOAEL: 3,000 mg/kg body weight
- Result: No effects on fertility and early embryonic development were detected.

- Test Type: Embryo-foetal development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
- Result: No effects on fertility and early embryonic development were detected.

Ivermectin:

Effects on fertility:
- Test Type: Fertility
- Species: Rat
- Application Route: Oral
- Fertility: NOAEL: 0.6 mg/kg body weight
- Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
- Test Type: Development
- Species: Mouse
- Application Route: Oral
- Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
- Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

- Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 0.4 mg/kg body weight
- Result: Embryotoxic effects and adverse effects on the offspring were detected.
- Remarks: The mechanism or mode of action may not be relevant in humans.

- Test Type: Development
- Species: Rabbit
- Application Route: Oral
- Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

STOT - single exposure
Not classified based on available information.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.17  Revision Date: 27.08.2021  SDS Number: 52862-00020  Date of last issue: 09.04.2021
Date of first issue: 02.02.2015

Components:

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs.

STOT - repeated exposure
Not classified based on available information.

Components:

Ivermectin:
Target Organs: Central nervous system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Species: Dog
NOAEL: 10 mg/kg
LOAEL: 30 mg/kg
Application Route: Ingestion
Exposure time: 3 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 600 mg/kg
Application Route: Oral
Exposure time: 19 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 600 mg/kg
Application Route: Oral
Exposure time: 30 d
Remarks: No significant adverse effects were reported

Species: Dog
NOAEL: 600 mg/kg
Application Route: Oral
Exposure time: 90 d
Remarks: No significant adverse effects were reported

Ivermectin:
Species: Dog
NOAEL: 0.5 mg/kg
LOAEL: 1 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Ivermectin / Pyrantel Formulation

Target Organs: Central nervous system
Symptoms: Dilatation of the pupil, Tremors, Lack of coordination, anorexia
Species: Monkey
NOAEL: 1.2 mg/kg
Application Route: Oral
Exposure time: 2 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 0.4 mg/kg
LOAEL: 0.8 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: spleen, Bone marrow, Kidney

Aspiration toxicity
Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:
Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:
4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):
Ingestion: Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Fever

Ivermectin:
Skin contact: Remarks: Can be absorbed through skin.
Eye contact: Remarks: May irritate eyes.
Ingestion: Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination
SECTION 12: Ecological information

12.1 Toxicity

**Components:**

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

**Ecotoxicology Assessment**

Acute aquatic toxicity: Toxic effects cannot be excluded

Chronic aquatic toxicity: Toxic effects cannot be excluded

**Ivermectin:**

Toxicity to fish:
- LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l Exposure time: 96 h
- LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): 0.000025 mg/l Exposure time: 48 h

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l Exposure time: 72 h Method: OECD Test Guideline 201

**M-Factor (Acute aquatic toxicity)**: 10,000

**M-Factor (Chronic aquatic toxicity)**: 10,000

12.2 Persistence and degradability

**Components:**

**Ivermectin:**

Biodegradability: Result: Not readily biodegradable.
- Biodegradation: 50 % Exposure time: 240 d
12.3 Bioaccumulative potential

**Components:**

**Ivermectin:**
- Bioaccumulation: Bioconcentration factor (BCF): 74
- Partition coefficient: n-octanol/water: log Pow: 3.22

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment

**Product:**
- Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
- Assessment: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects
No data available

**SECTION 13: Disposal considerations**

13.1 Waste treatment methods

**Product:**
- Dispose of in accordance with local regulations.
- According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
- Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:**
- Empty containers should be taken to an approved waste handling site for recycling or disposal.
- If not otherwise specified: Dispose of as unused product.

**SECTION 14: Transport information**

14.1 UN number or ID number

**ADN:** UN 3077
**ADR:** UN 3077
**RID:** UN 3077
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version: 2.17
Revision Date: 27.08.2021
SDS Number: 52862-00020
Date of last issue: 09.04.2021
Date of first issue: 02.02.2015

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)</td>
</tr>
<tr>
<td>RID</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)</td>
</tr>
<tr>
<td>IMDG</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ivermectin)</td>
</tr>
<tr>
<td>IATA</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Ivermectin)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

| ADN | 9 |
| ADR | 9 |
| RID | 9 |
| IMDG| 9 |
| IATA| 9 |

14.4 Packing group

<table>
<thead>
<tr>
<th>ADN</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
</tr>
<tr>
<td>Classification Code</td>
<td>M7</td>
</tr>
<tr>
<td>Hazard Identification Number</td>
<td>90</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADR</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
</tr>
<tr>
<td>Classification Code</td>
<td>M7</td>
</tr>
<tr>
<td>Hazard Identification Number</td>
<td>90</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
<tr>
<td>Tunnel restriction code</td>
<td>(-)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RID</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
</tr>
<tr>
<td>Classification Code</td>
<td>M7</td>
</tr>
<tr>
<td>Hazard Identification Number</td>
<td>90</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMDG</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td>Packing group</td>
<td>III</td>
</tr>
<tr>
<td>Labels</td>
<td>9</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.17  Revision Date: 27.08.2021  SDS Number: 52862-00020  Date of last issue: 09.04.2021

Date of first issue: 02.02.2015

EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN Environmentally hazardous : yes

ADR Environmentally hazardous : yes

RID Environmentally hazardous : yes

IMDG Marine pollutant : yes

IATA (Passenger) Environmentally hazardous : yes

IATA (Cargo) Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Ivermectin / Pyrantel Formulation

Version 2.17  Revision Date: 27.08.2021  SDS Number: 52862-00020  Date of last issue: 09.04.2021

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable

<table>
<thead>
<tr>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H300: Fatal if swallowed.
H311: Toxic in contact with skin.
H370: Causes damage to organs if swallowed.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
STOT RE: Specific target organ toxicity - repeated exposure
STOT SE: Specific target organ toxicity - single exposure
IE OEL: Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA): Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Con-
centration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information


Classification of the mixture:  Classification procedure:

Aquatic Acute 1  H400  Calculation method
Aquatic Chronic 1 H410  Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN